Having trouble viewing this email? View in your browser.
ESCMID Logo

12 February 2019
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,

ESCMID Executive Office.

 

Upcoming GARDP webinar on NIAID Resources to Facilitate Discovery & Development of Anti-Infectives – February 21, 17:00-18:30 (CET)

Our colleagues at GARDP are hosting a webinar, where Ann Eakin (US National Institute of Allergy and Infectious Diseases, NIAID) will provide an overview of the various mechanisms of support offered by NIAID to facilitate the discovery and development of drugs, vaccines and diagnostics targeting infectious diseases. The types of support that will be discussed are grants and contracts, as well as preclinical and clinical research services that aim to reduce risk and advance product development efforts. Researchers from any country and from any type of institution (academia, industry, non-profit) are eligible to apply for nearly all types of support mechanisms offered by NIAID, irrespective of prior or current NIH funding.

Ann's presentation will be complemented by a short presentation of Dan Pevear, Founder and Senior Vice President, Biology and Grants Development, VenatoRx Pharmaceuticals, in which he will share VenatoRx' experience with NIAID support mechanisms.

The presentations will be followed by a Q&A session.

You can register at the GARDP website.

› Read more
OPEN CALLS | APPLICATIONS

Latebreaker abstract submission for ECCMID 2019

Latebreaker abstract submission for ECCMID 2019 is now open!

This is a great opportunity for those with recently-completed research to present their work!

Visit the ECCMID website to view the guidelines and to submit your abstract, submissions close on February 18!

› Read more

3rd ESCMID Course on Encephalitis, Grenoble, France – 26-28 June 2019

ESCMID is pleased to announce the opening of registrations of the 3rd course on Encephalitis. Sign up now for a 2-day update on the diagnosis, management and treatment of CNS infections.

Attendance grants are available for ESCMID Young Scientist Members.

› Read more
 

CMI highlight: new guidelines for the decolonisation of carriers of multidrug-resistant Gram-negatives

The new ESCMID-EUCIC recommendations for decolonising regimens targeting multidrug-resistant Gram-negative bacteria carriers in all settings have been just published in CMI.

The evidence-based guidelines focus on carriers of third-generation cephalosporin-resistant Enterobacteriaceae (3GCephRE), carbapenem-resistant Enterobacteriaceae (CRE), aminoglycoside-resistant Enterobacteriaceae (AGRE), fluoroquinolone-resistant Enterobacteriaceae (FQRE), extremely drug-resistant Pseudomonas aeruginosa (XDRPA), carbapenem-resistant Acinetobacter baumannii (CRAB), cotrimoxazole-resistant Stenotrophomonas maltophilia (CRSM), colistin-resistant Gram-negative organisms (CoRGNB), and pan-drug-resistant Gram-negative organisms (PDRGNB).

Four types of outcomes were evaluated:

1) microbiological outcomes (carriage and eradication rates) at treatment end and at specific post-treatment time points;

2) clinical outcomes (attributable and all-cause mortality and infection incidence) at the same time points and length of hospital stay;

3) epidemiological outcomes (acquisition incidence, transmission and outbreaks); and

4) adverse events of decolonisation (including resistance development).

The level of evidence for and strength of each recommendation were defined according to the GRADE approach. Please note the panel does not recommend routine decolonisation of 3GCephRE and CRE carriers.

The guidance document identifies unmet needs and includes suggestions for new clinical trials where evidence is much needed.

› Read more
 

New dates for the ESGFOR postgraduate course in Zagreb: Challenges in the diagnosis of life-threatening infections.

New dates: 10-12 October 2019. Course Venue: Palace Hotel, Zagreb

This course focuses on the clinical, molecular and forensic diagnosis of life-threatening infections caused by classical and emerging pathogens. Topics are sepsis and respiratory infections in both the community and the ICU, antimicrobial resistance, viruses causing life-threatening infections, fulminant infection patterns, preparedness in outbreak settings, microbiological sampling and molecular diagnostic techniques. More than 15 European renowned faculty members will contribute to an update on the clinical and pathological signs observed and to assess the range of diagnostic assays available. A practical approach is added with case discussions and visual material. At the end of the course, participants will have acquired keys for the early diagnosis of life-threatening infections and they will understand the importance of the interaction between microbiological and pathological results. They will have learned for which pathological and microbiological findings to be alerted in the search for the aetiology of a sudden death cause. The target audience are microbiologists, clinicians, infectious disease physicians, molecular biologists, pathologists, and forensic physicians. The full program will be available on the ESCMID website in the coming week. Attendance grants for ESCMID “young scientist members” will be provided.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.